Neitzel et al., Liebigs Ann. Chem., 1907-1912 (1980). |
Howbert et al., Multiple Cholecystokinin Receptors-Progress Toward CNS Therapeutic Targets Abstract, Harlow, England, Sep. 20-22, 1990. |
Hodgkiss, et al. Multiple Cholecystokinin Receptors-Progress Toward CNS Therapeutic Targets Abstract, Harlow, England, Sep. 20-22, 1990. |
Lucaites et al., Soc. Neurosci. Abstr. 16:82, 1990. |
Howbert et al., Soc. Neurosci. Abstr. 16:82, 1990. |
Howbert, Joint Great Lakes-Central Regional Meeting of American Chemical Society, Indianapolis, Ind., May 29-31, 1991. |
Howbert, Invited Lectures, McGill University (Nov. 28, 1990), Univ. Sherbrook (Nov. 29, 1990), Indiana Univ. School of Med. (Dec. 4, 1990; Dec. 6, 1990), Johns Hopkins Univ. (Jan. 29, 1991) Howbert, Society for Drug Research, London, England, Mar. 21, 1991. |
Rasmussen, Methods of Evaluation for Psychopharmacology, Butler Universty, Indianapols, Ind., Apr. 23, 1993. |
Howbert et al., LY288513, an Antagonist of Brain Cholecystokinin Receptors, American College of Neurospychopharmacology, San Juan, Puerto Rico, Dec. 14-18, 1992. |
Palmour et al., Anxiogenic Effects of CCK Agonists in a Non-human Primate Model: Central or Peripheral?, International Symposium, Chatham, Mass., May 19-22, 1993. |
Howbert et al., Differential Ability of a Pyrazolidinone Type A CCK Receptor Antagonist to Block the Gastric Inhibitory and Pyloric Contractile Actions of CCK, International Symposium, Chatham, Mass., May 19-22, 1993. |
Howbert et al., CCK.sub.B Receptors Tonically Modulate a 10 Dopaminergic Neurons: Neurochemical Evaluation of LY288513, Annual Society for Neuroscience Meeting, Washington, D.C., Nov. 7-12, 1993. |
Tollefson, CCK Antagonist and Other Related Neuropeptides as Anxiolytics, First International Congress on Hormones, Brain and Neuropsychopharmacology, Sep. 1993. |
Schmidt et al., Behavioral and Electrophysiological Characterization of the New Cholecystokinin (CCK)-B Antagonist LY288513, Society for Neuroscience Meeting, Washington, D.C., Nov. 1993. |
Hughes et al., Development of a Class of Selective Cholecystokinin Type B Receptor Antagonists having Potent Anxiolytic Activity, Proc. Natl., Acad. Sci. USA, 87:6728-6732, 1990. |
Bock, Development of Non-Peptide Cholecystokinin Type B Receptor Antagonists, Drugs of the Future, 16(7):631-640, 1991. |
Staley et al., CCK Antagonists Interact with CCK-B Receptors on Human Small Cell Lung Cancer Cells, Peptides, 11(5):1033-6, Sep.-Oct., 1990. |
Greenwood et al., Mechanisms by Which CCK-8 Stimulates Gallbladder and Colonic Motility in the Ferret, American Gastroenterological Association/American Association for the Study of Liver Diseases, Abstr., Boston, Mass., May 16-19, 1993. |
Greenwood et al., CCK-8 Contracts the Gallbladder and Colon Through Different Mechanisms in the Ferret, New York Academy of Sciences, Jul. 15, 1993. |
Singh et al., The Antagonism of Benzodiazepine Withdrawal Effects by the Selective Cholecystokinin .sub.B B Receptor Antagonist CI-988, Br. J. Pharmacol., 105, 8-100, 1992. |
Rasmussen et al., The CCK-B Antagonist LY288513 Blocks Diazepam-Withdrawal-Induced Increases in Auditory Startle Response, Abstr., New York Academy of Sciences, Jul. 15, 1993. |
Rasmussen, CCK, Schizophrenia, and Anxiety: CCK-B Antagonists Inhibit the Activity of Brain Dopamine Neurons, New York Academy of Sciences Jul. 15, 1993. |
Rasmussen et al., Electrophysiological Effects of Diphenylpyrazolidinone CCK-B and CCK-A Antagonists on Midbrain Dopamine Neurons, The Journal of Pharmacology and Experimental Therapeutics, (accepted Sep. 1992). |
Iyengar, CCK.sub.B Receptors Tonically Modulate A10 Dopaminergic Neurons: Neurochemical Evaluation of LY288513, International Symposium, Cape Cod, May 19-22, 1993. |
Boyce et al., Modulatory Role for CCK-B Antagonists in Parkinson's Disease, Clinical Neuropharmacology, 13:339-347, 1990. |
Rasmussen, Quinazolinone CCK-B Antagonists Decrease the Number of Spontaneously Active Dopamine Neurons, Society for Neuroscience Convention, Anaheim, Calif., Oct. 26, 1992. |
Rasmussen et al., Cholecystokinin (CCK) and Schizophrenia: The Selective CCK.sub.B Antagonist LY262691 Decreases Midbrain Dopamine Unit Activity, European Journal of Pharmacology, 209:135-138, 1991. |
Palmour et al., Anxiogenic and Cardiovascular Effects of CCK-4 in Monkeys are Blocked by the CCK-B Antagonist LY262691, Society for Neuroscience Meeting, 1991 Annual Meeting, New Orleans, La., Aug. 1991. |
Howbert et al., A Novel Series of Non-Peptide CCK and Gastrin Antagonists: Medicinal Chemistry and Electrophysiological Demonstration of Antagonism, CCK symposium, Harlow, England, Oxford University Press 29-37, 1992. |
Totterdell et al., Cholecystokinin-Immunoreactive Boutons in Synaptic Contact with Hippocampal Pyramidal Neurons that Project to the Nucleus Accumbens, Neuroscience, 19:181-192, 1986. |
Rasmussen et al., Electrophysiological Effects of Diphenylpyrazolidinone Cholecystokinin-B and Cholecystokinin-A Antagonists on Midbrain Dopamine Neurons, Journal of Pharmacology and Experimental Therapeutics, 264:480-488, 1993 (Accepted Sep. 8, 1992). |
Rasmussen et al., Inihbition of A9 and A10 Dopamine Cells by the Cholecystokinin-B Antagonist LY262691: Mediation Through Feedback Pathways From Forebrain Sites, Synapse, 15:95-103, 1993. |
Rasmussen et al., The CCK-B Antagonist LY288513 Blocks Effects of Diazepam Withdrawal on Auditory Startle, NeuroReport, 5:154-156, 1993. |
Yu, et al., Quinazolinone CCK-B antagonists decrease the number of spontaneously active dopamine neurons, Soc. for Neurosc. Abstr. (1992)278. |